NCT05994599

Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring

SINGLE DOSE CROSSOVER COMPARATIVE BIOAVAILABILITY STUDY OF ETHINYL ESTRADIOL/ETONOGESTREL VAGINAL RING (DELIVERING 0.015 mg/0.12 mg PER DAY) WORN FOR 21 DAYS IN HEALTHY FEMALE SUBJECTS

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Evestra Inc. · Industry
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Single Dose Crossover Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (Delivering 0.015 mg/0.12 mg Per Day) Worn for 21 Days in Healthy Female Subjects

Conditions

• Healthy Women
• Female
• Contraception

Interventions

Type	Name	Description
COMBINATION_PRODUCT	EVE119 vaginal ring	EVE119 (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day
COMBINATION_PRODUCT	Nuvaring vaginal ring	Nuvaring® (ethinyl estradiol/etonogestrel) vaginal ring delivering 0.015 mg/0.12 mg dose per day

Timeline

• Start date: 2023-07-29
• Primary completion: 2023-12-11
• Completion: 2023-12-11
• First posted: 2023-08-16
• Last updated: 2024-06-24

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study